Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury
AssigneeFidia S.p.A.
InventorsGino Toffano, Alberta Leon, Marino Massarotti
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM1. Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM1 and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.
Claims12
A method for the treatment of spinal-cord damage which comprises administering an effective amount of ganglioside GM1 to a patient in need thereof.
Use of the ganglioside GM1 for the manufacture of a pharmaceutical composition for the treatment of spinal-cord damage.
Use of the ester of methylprednisolone with hyaluronic acid for the manufacture of a pharmaceutical composition for the treatment of spinal-cord injury.
Dependencies are inferred from the claim text.